Survival in infection‐related acute‐on‐chronic liver failure is defined by extrahepatic organ failures

Jasmohan S. Bajaj, Jacqueline G. O'Leary, K. Rajender Reddy, Florence Wong, Scott W. Biggins, Heather Patton, Michael B. Fallon, Guadalupe Garcia‐Tsao, Benedict Maliakkal, Raza Malik, Ram M. Subramanian, Leroy R. Thacker, Patrick S. Kamath, the North American Consortium for the Study of End-stage Liver Disease (NACSELD) – 20 February 2014 – Infections worsen survival in cirrhosis; however, simple predictors of survival in infection‐related acute‐on‐chronic liver failure (I‐ACLF) derived from multicenter studies are required in order to improve prognostication and resource allocation.

Late hepatic artery thrombosis after pediatric liver transplantation: A cross‐sectional study of 34 patients

Jesper M. Kivelä, Silja Kosola, Teija Kalajoki‐Helmiö, Heikki Mäkisalo, Hannu Jalanko, Christer Holmberg, Mikko P. Pakarinen, Jouni Lauronen – 18 February 2014 – Hepatic artery thrombosis (HAT) after liver transplantation (LT) increases patient morbidity and mortality. Early HAT is considered to occur within the first month after LT, whereas late HAT occurs after the first month. Few studies have addressed late HAT after LT, especially in pediatric patients. Between 1987 and 2007, 99 patients (age < 18 years) underwent deceased donor LT.

Potential impacts of the Affordable Care Act on the clinical practice of hepatology

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Potential impacts of the Affordable Care Act on the clinical practice of hepatology

Jayant A. Talwalkar – 15 February 2014 – The Patient Protection and Affordable Care Act (ACA), along with the Health Care and Education Reconciliation Act, was signed into law and upheld by the Supreme Court earlier this year. The ACA contains a variety of reforms that, if implemented, will significantly affect current models of healthcare delivery for patients with acute and chronic hepatobiliary diseases.

Blockade of CD47‐mediated cathepsin S/protease‐activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma

Terence Kin‐Wah Lee, Vincent Chi‐Ho Cheung, Ping Lu, Eunice Yuen Ting Lau, Stephanie Ma, Kwan Ho Tang, Man Tong, Jessica Lo, Irene Oi Lin Ng – 12 February 2014 – Identification of therapeutic targets against tumor‐initiating cells (TICs) is a priority in the development of new therapeutic paradigms against cancer. We enriched a TIC population capable of tumor initiation and self‐renewal by serial passages of hepatospheres with chemotherapeutic agents. In chemoresistant hepatospheres, CD47 was found to be up‐regulated, when compared with differentiated progenies.

Subscribe to